Andrew R Reynolds

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10767810/publications.pdf

Version: 2024-02-01

		186265	330143
38	5,190	28	37
papers	citations	h-index	g-index

40	40	40	8761
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. British Journal of Cancer, 2022, 127, 988-1013.	6.4	30
2	Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases. Communications Biology, 2021, 4, 950.	4.4	26
3	Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis, 2020, 23, 55-74.	7.2	77
4	Vessel co-option in cancer. Nature Reviews Clinical Oncology, 2019, 16, 469-493.	27.6	285
5	Non-angiogenic tumours and their influence on cancer biology. Nature Reviews Cancer, 2018, 18, 323-336.	28.4	113
6	Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. Radiology, 2018, 288, 739-747.	7.3	34
7	The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. European Journal of Cancer, 2017, 75, 245-258.	2.8	82
8	Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI. Cancer Research, 2017, 77, 4127-4134.	0.9	26
9	The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization. Journal of Pathology, 2017, 241, 441-447.	4.5	8
10	International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. British Journal of Cancer, 2017, 117, 1427-1441.	6.4	172
11	Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. Journal of Pathology, 2017, 241, 362-374.	4.5	162
12	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	27.6	792
13	Apatinib for the treatment of gastric cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-6.	3.0	51
14	Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. Journal of the National Cancer Institute, 2016, 108, djw030.	6.3	144
15	Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nature Medicine, 2016, 22, 1294-1302.	30.7	342
16	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Current Biology, 2016, 26, 755-765.	3.9	57
17	Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models. Cancer Research, 2016, 76, 787-795.	0.9	133
18	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 172-183.	4.1	35

#	Article	IF	Citations
19	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. Ecancermedicalscience, 2015, 9, 553.	1.1	0
20	Mechanism of tumour vascularization in experimental lung metastases. Journal of Pathology, 2015, 235, 384-396.	4.5	53
21	Tumor Stromal Phenotypes Define VEGF Sensitivityâ€"Letter. Clinical Cancer Research, 2014, 20, 5140-5140.	7.0	4
22	Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis, 2014, 17, 471-494.	7.2	626
23	Bevacizumab beyond progression in breast cancer. Lancet Oncology, The, 2014, 15, 1190-1191.	10.7	2
24	The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer. Clinical Cancer Research, 2013, 19, 6924-6934.	7.0	62
25	The Multifaceted Role of the Microenvironment in Liver Metastasis: Biology and Clinical Implications. Cancer Research, 2013, 73, 2031-2043.	0.9	177
26	Essential Role for Endocytosis in the Growth Factor-stimulated Activation of ERK1/2 in Endothelial Cells. Journal of Biological Chemistry, 2013, 288, 7467-7480.	3.4	60
27	Contrasting effects of sunitinib within in vivo models of metastasis. Angiogenesis, 2012, 15, 623-641.	7.2	74
28	Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer. Dose-Response, 2010, 8, dose-response.0.	1.6	95
29	Endothelial Î±3Î²1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. American Journal of Pathology, 2010, 177, 1534-1548.	3.8	54
30	Î±vÎ²3 Integrin Limits the Contribution of Neuropilin-1 to Vascular Endothelial Growth Factor-induced Angiogenesis. Journal of Biological Chemistry, 2009, 284, 33966-33981.	3.4	88
31	Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine, 2009, 15, 392-400.	30.7	428
32	Reply to: â€œWill integrin inhibitors have proangiogenic effects in the clinic?â€• Nature Medicine, 2009, 15, 727-727.	30.7	6
33	Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis. Angiogenesis, 2008, 11, 337-346.	7.2	11
34	Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in Î²3-Integrinâ€"Deficient Mice. Cancer Research, 2004, 64, 8643-8650.	0.9	148
35	Integrins in angiogenesis: multitalented molecules in a balancing act. Cell and Tissue Research, 2003, 314, 131-144.	2.9	142
36	EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nature Cell Biology, 2003, 5, 447-453.	10.3	218

#	Article	IF	Citations
37	Nanoparticle-mediated gene delivery to tumour neovasculature. Trends in Molecular Medicine, 2003, 9, 2-4.	6.7	47
38	Quantitative Imaging of Lateral ErbB1 Receptor Signal Propagation in the Plasma Membrane. , 2000, 290, 1567-1570.		319